Refine by
Cardiac Function Articles & Analysis
25 news found
Hemostemix Inc. (TSX-V: HEM; OTCQB: HMTXF; FSE: 2VF0), the leading autologous (patient’s own) stem cell therapy company offering treatments for no-option patients in Florida suffering from Chronic Limb Threatening Ischemia, Peripheral Arterial Disease, Angina, Ischemic Cardiomyopathy, non Ischemic Dilated Cardiomyopathy, and Congestive Heart Failure, is pleased to announce additions to ...
However, the mechanisms by which LFS impacts these functions remain inadequately understood. This blog focuses on a new publication from Gomez et al (2024) on how LFS exposure impairs respiratory and cardiac health, with a special focus on the role of the flexiVent system in measuring the respiratory function effects. ...
(PMD) developed a percutaneous heart pump designed to support cardiac and renal function in patients with advanced heart failure (HF). ...
(PMD) developed a percutaneous heart pump designed to support cardiac and renal function in patients with advanced heart failure (HF). ...
Bodyport, a medtech company based in San Francisco, developed the Bodyport Cardiac Scale, a set of weighing scales that can non-invasively assess fluid status and heart function. ...
There was a near normalization of diuretic response with six-hour excretion of sodium more than doubling vs. baseline, as well as a considerable improvement in cardio-renal health, with a mean reduction in NT-proBNP, a key cardiac function parameter, of more than 30% vs. baseline and a stable renal function (eGFR[v]) vs. baseline despite this ...
rst-in-human study to evaluate the performance of its ModulHeart percutaneous heart pump designed to reduce cardiac afterload and improve renal perfusion in patients with advanced heart failure (HF). ...
Likewise, measures of RV systolic function including right ventricular fractional area change (RVFAC) and tricuspid annular plane systolic excursion (TAPSE), improved by 5.59.1 absolute % and 1.52.5 mm, respectively, regardless of baseline LVEF (p less than 0.0001 for both). ...
The published results showed statistically significant and clinically relevant evidence of CAP-1002’s ability to improve both skeletal and cardiac muscle function in patients in the latter stages of the disease. ...
Adverse Device Effect (ADE) rate at 30 days post index procedure will be assessed as the primary endpoint. In addition, cardiac function and clinical safety endpoints - including death, heart failure-related hospitalization, new onset or worsening of heart failure – will be assessed. ...
Specifically, the study demonstrated that young men in the advanced stages of DMD experienced improvements in both skeletal and cardiac muscle function after receiving four doses of CAP-1002 over the course of one year. ...
Across the study population, the treatment reduced the rate at which upper limb function declined and also improved cardiac function. It is important to understand the real differences this treatment can potentially make in patients’ lives. ...
The CardiAMP Cell Therapy Heart Failure Trial is evaluating the effectiveness of the CardiAMP Cell Therapy System for improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for New York Heart Association (NYHA) Class II and III patients who have heart failure associated with ischemic cardiomyopathy. ...
It is believed to be the first cardiac cell therapy to receive FDA Breakthrough Device status. CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure. ...
Levels < 86 ng/mL included among other things a lower risk of cardiovascular events (such as ventricular tachycardia, ventricular fibrillation, sudden cardiac death), improved cardiac function, and low fatty infiltration in the heart. ...
” “Pulsed Field Ablation as applied to the field of cardiac electrophysiology has enormous potential, given the expected improvements in safety, efficacy and speed over current therapies,” said Vince Burgess, President and CEO of Acutus Medical. “Our vision for the future of this new energy source is to deliver it via a force sensing focal point ablation ...
Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced today the schedule of presentations to be featured at the annual Transcatheter Cardiovascular Therapeutics (TCT) conference in Orlando, Florida from November 4th to November 6th. The presentations include a spotlight on the company’s first US ...
Kosmos has just released its pulsed-wave Doppler followed closely by continuous-wave Doppler functions, which is coming soon. With the world still in the grip of the pandemic in the short term, tailored POCUS training and curricula can deliver engaging and immersive new opportunities to supplement the medical curriculum. ...
Hanover, Germany, October 22, 2020 - Cardior Pharmaceuticals GmbH, a clinical-stage biotech company, focused on the development of noncoding RNA (ncRNA) therapeutics for patients with cardiovascular diseases, today announced a publication in the European Heart Journal (doi:10.1093/eurheartj/ehaa791) demonstrating that repeated treatment with its lead compound CDR132L is safe, improves ...
Acurable, a fast-growing medical device company, has announced the availability of its first product, AcuPebble SA100, a small wearable device which for the first time enables a fully automated and remote diagnosis of obstructive sleep apnoea (OSA). Traditionally, the diagnosis of OSA has required multiple hospital visits for patients, and doctors have had to manually review and analyse data from ...